Overview
- A California federal jury found Apple infringed U.S. Patent No. 10,433,776 covering low-power pulse oximetry, which expired in 2022.
- Jurors determined the Apple Watch qualifies as a "patient monitor" and based damages on roughly 43 million devices.
- The award aligns with Masimo’s requested range after Apple urged the court to limit damages to $3 million to $6 million.
- Apple said it will appeal, calling the case reliant on expired, decades-old technology and noting many Masimo claims were found invalid.
- In a separate track, the ITC has reopened a review of Apple’s redesigned blood-oxygen implementation, leaving potential import restrictions in play.